Is Chengdu Bright Eye Hospital Group (SZSE:301239) Using Too Much Debt?
Is Chengdu Bright Eye Hospital Group (SZSE:301239) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that Chengdu Bright Eye Hospital Group Co., Ltd. (SZSE:301239) does use debt in its business. But is this debt a concern to shareholders?
霍华德·马克斯说得很好,他说,与其担心股价波动,'我担心的是永久损失的可能性...我认识的每个实际投资者都会担心这个问题。' 当我们考虑一家公司的风险有多大时,我们总是喜欢看它的债务使用情况,因为债务过载可能导致灾难。我们可以看到成都明目医疗集团有限公司(SZSE:301239)在业务中确实使用了债务。但这种债务是否会让股东担忧呢?
What Risk Does Debt Bring?
债务带来了什么风险?
Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first step when considering a company's debt levels is to consider its cash and debt together.
当企业无法轻松地通过自由现金流或以有吸引力的价格筹集资本来履行义务时,债务和其他负债会对企业产生风险。最终,如果企业无法履行偿还债务的法定义务,则股东可能什么都拿不到。虽然这种情况并不常见,但我们经常看到负债累累的企业由于债权人强制他们以处于困境的价格筹集资本而长期稀释股东权益。当然,有很多公司使用债务来资助增长,没有任何负面后果。在考虑公司的债务水平时,第一步是考虑现金和债务的综合情况。
How Much Debt Does Chengdu Bright Eye Hospital Group Carry?
成都明目医疗集团承载了多少债务?
You can click the graphic below for the historical numbers, but it shows that as of June 2024 Chengdu Bright Eye Hospital Group had CN¥418.0m of debt, an increase on CN¥346.1m, over one year. But it also has CN¥647.2m in cash to offset that, meaning it has CN¥229.2m net cash.
您可以点击下方的图形查看历史数字,但截至2024年6月,成都明目医疗集团负债41800万人民币,较一年前的34610万人民币增加。但它也有64720万人民币的现金来抵消这笔债务,这意味着它有净现金22920万人民币。
A Look At Chengdu Bright Eye Hospital Group's Liabilities
查看成都明亮眼科医院集团的负债情况
According to the last reported balance sheet, Chengdu Bright Eye Hospital Group had liabilities of CN¥764.6m due within 12 months, and liabilities of CN¥1.72b due beyond 12 months. On the other hand, it had cash of CN¥647.2m and CN¥206.7m worth of receivables due within a year. So its liabilities total CN¥1.63b more than the combination of its cash and short-term receivables.
根据最近披露的资产负债表显示,成都明亮眼科医院集团有着12个月内到期的负债为7.646亿元人民币,以及超过12个月到期的负债为17.2亿元人民币。另一方面,该集团拥有6.472亿元人民币的现金和2.067亿元人民币的应收款项,这些都是一年内到期的。所以,它的负债总计比现金和短期应收款项的总和多了16.3亿元人民币。
Chengdu Bright Eye Hospital Group has a market capitalization of CN¥5.08b, so it could very likely raise cash to ameliorate its balance sheet, if the need arose. But we definitely want to keep our eyes open to indications that its debt is bringing too much risk. While it does have liabilities worth noting, Chengdu Bright Eye Hospital Group also has more cash than debt, so we're pretty confident it can manage its debt safely.
成都明亮眼科医院集团的市值为50.8亿元人民币,因此在需要时很有可能筹集资金改善其资产负债表。但我们确实要密切关注是否其债务带来了过多风险。虽然它有值得关注的负债,但成都明亮眼科医院集团拥有更多的现金而非债务,因此我们相当有信心它可以安全地管理债务。
Chengdu Bright Eye Hospital Group grew its EBIT by 9.3% in the last year. That's far from incredible but it is a good thing, when it comes to paying off debt. There's no doubt that we learn most about debt from the balance sheet. But it is future earnings, more than anything, that will determine Chengdu Bright Eye Hospital Group's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
上一年,成都明亮眼科医院集团的EBIt增长了9.3%。虽然距离不可思议还有一段距离,但对于偿还债务来说是一件好事。毫无疑问,我们从资产负债表中了解最多关于债务。但未来的盈利,比任何事情都将决定成都明亮眼科医院集团维持健康资产负债表的能力。因此,如果你专注于未来,可以查看这份免费报告,展示分析师的利润预测。
Finally, a company can only pay off debt with cold hard cash, not accounting profits. Chengdu Bright Eye Hospital Group may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. During the last three years, Chengdu Bright Eye Hospital Group burned a lot of cash. While investors are no doubt expecting a reversal of that situation in due course, it clearly does mean its use of debt is more risky.
最后,一家公司只能用冷硬现金而非会计利润偿还债务。成都明亮眼科医院集团可能在资产负债表上有净现金,但了解业务是如何将其息税折旧摊销前利润(EBIT)转化为自由现金流的表现仍然很有意思,因为这将影响其对债务的需求和管理能力。在过去三年中,成都明亮眼科医院集团消耗了大量现金。尽管投资者无疑期待这种情况能够逆转,但这显然确实意味着其债务使用更加风险。
Summing Up
总之
Although Chengdu Bright Eye Hospital Group's balance sheet isn't particularly strong, due to the total liabilities, it is clearly positive to see that it has net cash of CN¥229.2m. And it also grew its EBIT by 9.3% over the last year. So while Chengdu Bright Eye Hospital Group does not have a great balance sheet, it's certainly not too bad. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. To that end, you should be aware of the 3 warning signs we've spotted with Chengdu Bright Eye Hospital Group .
虽然成都明眼医院集团的资产负债表并不是特别强大,由于总负债,可以明显看到其净现金为22920万人民币。同时,过去一年其EBIt增长了9.3%。因此,虽然成都明眼医院集团的资产负债表不是很好,但也不算太糟糕。在分析债务时,资产负债表显然是需要关注的地方。然而,并不是所有的投资风险都存在于资产负债表中 - 远非如此。为此,您应该意识到我们发现的与成都明眼医院集团有关的3个警示信号。
If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.
如果您有兴趣投资能够在不负债的情况下增长利润的企业,请查看这份免费列表,其中列出了在资产负债表上拥有净现金的成长型企业。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。